Register pursuant to section 6(b) of the Act on July 29, 2015 (90 FR 45234).

Patricia A. Brink,

Director of Civil Enforcement, Antitrust Division.

[FR Doc. 2015–33267 Filed 1–5–16; 8:45 am]

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—National Chemical & Biological Defense Consortium

Notice is hereby given that, on November 13, 2015, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. ("the Act"), National Chemical & Biological Defense Consortium ("NCBDC") has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing (1) the identities of the parties to the venture and (2) the nature and objectives of the venture. The notifications were filed for the purpose of invoking the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances.

Pursuant to section 6(b) of the Act, the identities of the parties to the venture are: AbViro LLC, Bethesda, MD; Advanced Nuclear Devices Corporation, Hilton Head Island, SC; Aequor, Inc., Oceanside, CA; Aeterna Zentaris, Québec, CANADA; AlBiotech, Richmond, VA; Allied Technologies & Consulting, LLC, Frederick, MD; AMH Consulting, Potomac, MD; AntibioTx ApS, Hørsholm, DENMARK; Approach Robotics, Ridgecrest, CA; Aradigm Corporation, Hayward, CA; Artificial Cell Technologies, Inc., New Haven, CT; BalinBac Therapeutics, Inc., Princeton, NJ; Battelle Memorial Institute, Columbus, OH; BioFactura, Inc., Frederick, MD; BioStat Solutions, Inc., Frederick, MD; Burrell International Group, LLC, Frederick, MD; CACI, Arlington, VA; CFD Research Corporation, Huntsville, AL; CONTINUUS Pharmaceuticals, Inc., Woburn, MA; Creare LLC, Hanover, NH; CSC Government Solutions LLC, Falls Church, VA; CUBRC, Inc., Buffalo, NY; DALI Medical Devices Ltd., Yavne, ISRAEL; Design West Technologies Inc., Tustin, CA; Draper Laboratory, Cambridge, MA; Eagle Applied Science, San Antonio, TX; Emergent, Inc., North Charleston, SC; Equivital Inc., New York, NY; EZ-A Consulting, LLC, Bel

Air, MD; First Line Technology, Chantilly, VA; General Dynamics Information Technology, San Diego, CA; GeoVax Labs, Inc., Smyrna, GA; Ginkgo BioWorks, Boston, MA; Goldbelt Raven, LLC, Herndon, VA; Hackensack University Medical Center, Hackensack, NJ; iBio, Inc., New York, NY; IIT Research Institute, Chicago, IL; Immune Biosolutions, Inc., Québec, CANADA; Inficon, East Syracuse, NY; Integrated BioTherapeutics, Inc., Gaithersburg, MD; InvivoSciences Inc., Madison, WI; Jade Therapeutics, Inc., Salt Lake City, UT; JRAD, Stafford, VA; KD Analytical, Harrisburg, PA; Kestrel Corporation, Albuquerque, NM; Kinnear Pharmaceuticals, LLC, Columbus, OH; Kivatec, Greenville, SC; L-3 Communications, New York, NY; Latham BioPharm Group, Inc., Maynard, MA; Luminex Corporation, Austin, TX; MainStream Global Solutions, Robins, IA; Mapp Biopharmaceutical, Inc., San Diego, CA; MaxCyte, Inc., Gaithersburg, MD; Med-Ally, Canton, CT; MedPro Technologies, LLC, San Antonio, TX; Mesa Science Associates Inc., Frederick, MD; Michael T. Brown Consulting, LLC, Austin, TX; Microbial Robotics, LLC, Covington, KY; Mike Sellers & Associates, Beavercreek, OH; MLT Systems, Stafford, VA; MRI Global, Kansas City, MO; Nanotherapeutics, Inc., Alachua, FL; New York Blood Center Inc., New York, NY; Novici Biotech LLC, Vacaville, CA; Novozymes, Inc., Franklinton, NC; OrPro Therapeutics, Inc., San Diego, CA; Parsons, Washington, DC; Pertexa, Ridgecrest, CA; Philips, Foster City, CA; PrEP Biopharm, Rumson, NJ; Purdue University, West Lafayette, IN; QuickSilver Analytics, Belcamp, MD; Quintiles, Durham, NC; Rapid Pathogen Screening, Inc. (RPS), Sarasota, FL; Recursion Pharmaceuticals, Salt Lake City, UT; RTI International, Coraopolis, PA; San Diego State University, San Diego, CA; Science Applications International Corporation, McLean, VA; SciTech Services Inc., Havre De Grace, MD; Shield Analysis Technology, LLC, Manassas, VA; SIGA Technologies, Inc., New York, NY; Signature Science, Austin, TX; Smart Consulting Group, LLC, West Chester, PA; Southern Research Institute, Birmingham, AL; Southwest Research Institute, San Antonio, TX; Spero Therapeutics, Cambridge, MA; SRI International, Princeton, NJ; Strategic Solutions Integrated, Arlington, VA; TDA Research, Inc., Wheat Ridge, CO; Tetracore, Inc., Rockville, MD; Texas A&M, Bryan, TX; TheraSource LLC, Roslyn, NY; Trideum, Huntsville, AL; TriLink BioTechnologies, San Diego,

CA; Ubiquitome Limited, Auckland, NEW ZEALAND; University of Florida Institute for Therapeutic Innovation, Gainesville, FL; University of Nebraska Medical Center—Department of Pathology and Microbiology, Omaha, NE; University of North Texas Health Sciences Center, Fort Worth, TX; University of Pittsburgh—Center for Military Medicine Research, Pittsburgh, PA; and Vaxess Technologies, Inc., Cambridge, MA. The general area of NCBDC's planned activity is advanced development efforts to support the Department of Defense's medical pharmaceutical and diagnostic requirements as related to enhancing the mission effectiveness of military personnel through (i) detectionsystems and devices to identify CBRN (Chemical Biological Radiological and Nuclear) agents and assist in making medical decisions; (ii) preventionprophylaxis, pretreatment, and postexposure prophylaxis; (iii) treatment therapeutics (post-exposure, postsymptomatic); and (iv) chemical medical protection against use of chemical agents.

Patricia A. Brink,

Director of Civil Enforcement, Antitrust Division.

[FR Doc. 2015–33266 Filed 1–5–16; 8:45 am] **BILLING CODE P**

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—ASTM International Standards

Notice is hereby given that, on December 11, 2015, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. ("the Act"), ASTM International ("ASTM") has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing additions or changes to its standards development activities. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, ASTM has provided an updated list of current, ongoing ASTM standards activities originating between September 2015 and December 2015 designated as Work Items. A complete listing of ASTM Work Items along with a brief description of each, is available at http://www.astm.org.

On September 15, 2004, ASTM filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to section 6(b) of the Act on November 10, 2004 (69 FR 65226).

The last notification was filed with the Department on September 14, 2015. A notice was published in the **Federal Register** pursuant to section 6(b) of the Act on October 9, 2015 (80 FR 61236).

Patricia A. Brink,

Director of Civil Enforcement, Antitrust Division.

[FR Doc. 2015–33268 Filed 1–5–16; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Notice of Lodging of Proposed Consent Decree Under the Comprehensive Environmental Response, Compensation, and Liability Act ("CERCLA")

AGENCY: Department of Justice.

ACTION: Notice.

SUMMARY: On December 29, 2015, the Department of Justice lodged a proposed Consent Decree with the United States District Court for the Central District of California, Western Division, in the lawsuit entitled *United States and State of California Department of Toxic Substances Control* v. *AC Products, Inc., et al.* Civil Action No. 2:15–cv–09931.

The United States and the State of California filed this lawsuit under the Comprehensive Environmental Response, Compensation, and Liability Act ("CERCLA") against the following Defendants for recovery of response costs which each incurred to address environmental contamination at the Cooper Drum Company Superfund Site located in Los Angeles County, California ("the Site"): AC Products, Inc.; A. G. Layne, Inc.; Alpha Corporation of Tennessee Inc.; Ashland Inc.; Atlantic Richfield Company; Baker Petrolite LLC; Cargill, Incorporated; Castrol Industrial North America Inc.; Chemcentral Corp.; Chemical Waste Management, Inc.; Chevron U.S.A. Inc.; Coral Chemical Company; D.A. Stuart Company; Dunn-Edwards Corporation; Engineered Polymer Solutions, Inc.; ExxonMobil Oil Corporation; Gallade Chemical, Inc.; Hasco Oil Company, Inc.; Houghton International, Inc.; J.H. Mitchell & Sons Distributors, Inc.; Lockheed-Martin Corporation; Lonza Inc.; Lubricating Specialties Company; Mathisen Oil Co., Inc.; Pennzoil-Quaker State Company; Penreco; PolyOne Corporation; PPG Industries, Inc.;

PTM&W Industries Inc.; Quaker Chemical Corporation; Rathon Corp.; Shell Chemical LP; Shell Oil Company; SOCO West, Inc.; Southern California Edison; Southern Counties Oil Co.; Sta-Lube LLC f/k/a Sta-Lube, Inc.; Stuarts' Petroleum; Texaco Downstream Properties Inc.; The Boeing Company; The Valspar Corporation; Union Oil Company of California; and Univar USA Inc.

The complaint names the above-listed companies as Defendants based on their business relationship with the Cooper Drum Company which operated a drum reconditioning business at the Site and which accepted drums from each Defendant that contained residues of hazardous substances. The Complaint also seeks declaratory relief for all future costs to be incurred. The Consent Decree resolves these claims through the payment of \$5,539,266 to the United States and \$53,599 to the State of California in partial recovery of response costs. In addition, the Defendants are obligated under the Consent Decree to reimburse the United States and the State of California for all future response costs and to perform the remedial action that EPA selected for the Site. In return, the United States and the State of California agree not to sue the Defendants under sections 106 and 107 of CERCLA.

The publication of this notice opens a period for public comment on the Consent Decree. Comments should be addressed to the Assistant Attorney General, Environment and Natural Resources Division, and should refer to United States and State of California Department of Toxic Substances Control v. AC Products, Inc., et al. D.J. Ref. No. 90–11–2–09084. All comments must be submitted no later than thirty (30) days after the publication date of this notice. Comments may be submitted either by email or by mail:

To submit comments:	Send them to:
By email	pubcomment-ees.enrd@ usdoj.gov. Assistant Attorney General, U.S. DOJ—ENRD, P.O.
	Box 7611, Washington, DC 20044–7611.

During the public comment period, the Consent Decree may be examined and downloaded at this Justice Department Web site: http://www.justice.gov/enrd/consent-decrees. We will provide a paper copy of the Consent Decree upon written request and payment of reproduction costs. Please mail your request and payment to: Consent Decree Library, U.S. DOJ—

ENRD, P.O. Box 7611, Washington, DC 20044–7611.

Please enclose a check or money order for \$145.50 (25 cents per page reproduction cost × 582 pages) payable to the United States Treasury. For a paper copy without the exhibits and signature pages, the cost is \$24.00 (25 cents per page reproduction cost × 96 pages)

Maureen Katz,

Assistant Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division.

[FR Doc. 2015–33194 Filed 1–5–16; 8:45 am]

BILLING CODE 4410-15-P

DEPARTMENT OF LABOR

Office of the Secretary

National Advisory Committee for Labor Provisions of U.S. Free Trade Agreements; Notice of Open Meeting

AGENCY: Bureau of International Labor Affairs, U.S. Department of Labor. **ACTION:** Notice of open meeting,

February 2, 2016.

SUMMARY: Pursuant to the Federal Advisory Committee Act (FACA), as amended, 5 U.S.C. App. 2, the Office of Trade and Labor Affairs (OTLA) gives notice of a meeting of the National Advisory Committee for Labor Provisions of U.S. Free Trade Agreements ("Committee" or "NAC"), which was established by the Secretary of Labor. The purpose of the meeting is to discuss the implementation of the labor provisions of free trade agreements and to identify the Committee's priority countries and issues for 2016.

DATES: The Committee will meet on Tuesday, February 2, 2016, from 9:30 a.m. to 4:30 p.m.

ADDRESSES: The Committee will meet at the U.S. Department of Labor, 200 Constitution Avenue NW., Deputy Undersecretary's Conference Room, Washington, DC 20210.

FOR FURTHER INFORMATION CONTACT:

Donna Chung, Designated Federal Official, Office of Trade and Labor Affairs, Bureau of International Labor Affairs, U.S. Department of Labor, 200 Constitution Avenue NW., Room S–5004, Washington, DC 20210; phone (202) 693–4861 (not a toll free number); fax (202) 693–4784 (not a toll free number).

Individuals with disabilities wishing to attend the meeting should contact Ms. Chung no later than January 25, 2016, to obtain appropriate accommodations.